Postherpetic Neuralgia:
Why Pain Persists Long After the Rash Has Healed

1. Varicella-Zoster Virus Reactivation and Initial Nerve Injury

Herpes zoster results from reactivation of varicella-zoster virus (VZV) that has remained latent in dorsal root ganglia since primary varicella infection. Upon reactivation — triggered by immunosenescence, immunosuppression, or physiological stress — VZV replicates within ganglion neurons and travels antidromically along sensory nerve fibers to the skin, producing the characteristic dermatomal vesicular eruption.

The inflammatory and cytopathic effects of this viral replication cause acute ganglionitis and peripheral nerve injury. At the histopathological level, this manifests as axonal degeneration, segmental demyelination, and dense inflammatory infiltration of the affected dorsal root ganglion — changes that have been documented in post-mortem studies of patients with PHN. The severity of this acute nerve injury is the strongest predictor of subsequent PHN development: patients with severe prodromal pain, extensive skin involvement, and high acute viral load carry substantially elevated risk. This relationship underscores the importance of early antiviral therapy to limit the magnitude of initial neuronal damage.

2. Central Sensitization: The Mechanism of Chronicity

The transition from acute zoster pain to PHN reflects a fundamental shift in pain pathophysiology — from peripheral nociception driven by active viral inflammation to centrally maintained pain driven by maladaptive neuroplasticity. This process, termed central sensitization, is the mechanistic core of PHN chronicity and explains the otherwise paradoxical persistence of severe pain in the absence of ongoing tissue injury.

2.1 NMDA Receptor Upregulation in the Dorsal Horn

Sustained high-frequency firing of injured C and Aδ fibers releases glutamate and substance P into the dorsal horn synaptic cleft. Repeated activation removes the voltage-dependent magnesium block from NMDA (N-methyl-D-aspartate) receptors on second-order dorsal horn neurons, allowing calcium influx and triggering intracellular signaling cascades — notably PKC and PKA phosphorylation — that upregulate receptor sensitivity and lower the neuronal activation threshold. Once established, this sensitized state can be maintained by afferent input levels that were previously subthreshold, or even without peripheral input at all.

2.2 Deafferentation and Loss of Inhibitory Interneurons

VZV-mediated destruction of dorsal root ganglion neurons produces deafferentation of dorsal horn circuits. This loss of primary afferent input removes tonic activation of inhibitory glycinergic and GABAergic interneurons in the superficial dorsal horn — a process termed deafferentation-induced disinhibition. The result is a profound reduction in the inhibitory counterbalance to ascending nociceptive transmission, effectively opening the "pain gate" in a manner analogous to that proposed by the original Melzack-Wall gate control theory.

2.3 Expansion of Receptive Fields

Central sensitization is associated with expansion of dorsal horn neuronal receptive fields, such that neurons originally responding only to input from the injured dermatome begin responding to stimuli from adjacent, uninjured skin. This explains the clinically observed spread of allodynia beyond the boundaries of the acute zoster eruption — a hallmark of established PHN that can encompass large areas of the trunk or limb.

3. Clinical Manifestations of PHN

The sensory phenotype of PHN is heterogeneous, reflecting the mixed contributions of peripheral sensitization, central sensitization, and deafferentation to symptom generation. Most patients experience a combination of the following:

4. Risk Determinants

PHN does not affect all herpes zoster patients equally. Risk stratification at the time of acute zoster presentation allows identification of patients requiring the most intensive early management.

• Age: The dominant risk factor. PHN probability rises from approximately 5% in those under 40 to 40–50% in those over 60, reflecting immunosenescence and age-related impairment of neural repair mechanisms including reduced Schwann cell proliferative capacity and slower axonal regeneration rates.
• Acute pain severity: Independently predictive across multiple cohort studies. High-intensity prodromal and acute pain indicates more extensive acute neuroinflammation and greater dorsal horn sensitization — both of which promote PHN development.
• Rash severity and extent: Larger or more confluent eruptions correlate with greater viral load and more extensive dorsal root ganglion involvement.
• Immunocompromise: Conditions impairing cell-mediated immunity — HIV infection, malignancy, transplantation, high-dose corticosteroids — increase both zoster incidence and PHN risk.
• Ophthalmic involvement: Herpes zoster ophthalmicus (trigeminal V1 branch) carries particularly high PHN risk, with associated risks to vision that compound the burden.

5. Nocturnal Exacerbation

A clinically consistent observation in PHN is the characteristic worsening of pain during evening and nighttime hours — often the most distressing aspect for patients whose daytime symptoms may be manageable. This nocturnal exacerbation is attributable to the diurnal rhythm of endogenous cortisol secretion. Cortisol, which exerts potent anti-inflammatory effects by suppressing NF-κB-dependent cytokine production, reaches its physiological nadir between midnight and the early morning hours. At this nadir, tonic suppression of neuroinflammatory signaling is withdrawn, permitting greater cytokine activity around sensitized dorsal horn circuits. Simultaneously, the removal of daytime attentional distraction unmasks the full amplitude of centrally sensitized pain processing.

6. Nutritional Adjuncts: Mechanistic Rationale

Pharmacological management of PHN — anticonvulsants (pregabalin, gabapentin), tricyclic antidepressants, topical lidocaine, capsaicin — addresses symptom modulation but does not target the underlying neuroinflammatory and oxidative mechanisms driving central sensitization. Nutritional adjuncts with specific mechanistic relevance to PHN pathophysiology offer a complementary approach.

6.1 Methylcobalamin (Active Vitamin B12)

Methylcobalamin supports myelin synthesis and axonal repair through its role as the essential cofactor for methionine synthase — the enzyme catalyzing homocysteine-to-methionine conversion in the methionine cycle. In the context of PHN, where VZV-mediated demyelination of affected sensory fibers contributes to aberrant pain signaling, adequate methylcobalamin status provides the biochemical substrate for myelin repair. In addition, methylcobalamin-dependent SAM generation supports the methylation reactions necessary for neurotransmitter synthesis, including serotonin and dopamine precursors involved in descending pain modulation.

6.2 Alpha-Lipoic Acid

Alpha-lipoic acid (ALA) addresses the oxidative stress component of PHN pathophysiology. As a dual-phase antioxidant active in both aqueous and lipid cellular compartments, ALA quenches reactive oxygen species generated by inflammatory activation in sensitized dorsal root ganglion neurons and dorsal horn circuits. Its unique capacity to regenerate glutathione, vitamin C, and vitamin E amplifies the antioxidant network. Additionally, ALA's mitochondrial cofactor activity supports the high energetic demands of repair-active neurons in the healing phase of PHN.